Home / Market News / $PCRX
fiscal.ai Corporate Catalyst Impact 80/100 ● negative

Pacira BioSciences Reports Third-Quarter 2026 Financial Results

Nov 6, 2026, 2:04 PM UTC · Primary ticker $PCRX

Pacira BioSciences reported a 2% year-over-year revenue decline in Q3 2026, but saw growth in its key products, EXPAREL and ZILRETTA. Earnings were positively impacted by a contingent consideration gain and a divestiture gain from the iovera° business sale, providing a mixed financial picture for investors.

Pacira BioSciences reported Q3 2026 financial results, showing a 2% year-over-year revenue decline to $176.65 million. This decline is a negative signal, but was partially offset by 2% growth in EXPAREL sales and 3% growth in ZILRETTA sales, indicating underlying strength in core products. Earnings were significantly bolstered by a $14.4 million contingent consideration gain and a $6.6 million divestiture gain from the sale of its iovera° business to Zimmer, which completed in July. For traders, the short-term implications are mixed: revenue is down, but core product growth and one-time gains provide a cushion. The long-term outlook will depend on continued product growth and pipeline advancements like the ASCEND study for PCRX-201, with results expected by year-end. The key opportunity lies in the potential positive data from the PCRX-201 study, which could re-rate the stock despite the current revenue dip.

$PCRX neutral Mixed Q3 results with revenue decline offset by product growth and gains
$ZBH neutral Acquired iovera° business from Pacira, completed in Q3
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.